Reverse phase protein microarrays and their utility in drug development

Methods in Molecular Biology

Volumn 986, Issue , 2013, Pages 187-214

  Sereni, Maria Isabella ^a   Pierobon, Mariaelena ^a   Angioli, Roberto ^a   Petricoin, Emanuel F ^a   Frederick, Mitchell J ^a  

^a NONE

Author keywords

Biomarkers; Drug development; Drug discovery; Reverse phase protein microarrays; RPMA; RPMA in Drug Development

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; PROTEIN;

ARTICLE; COMPARATIVE STUDY; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG MIXTURE; DRUG TARGETING; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN MICROARRAY; TREATMENT RESPONSE; VALIDATION STUDY; METHODOLOGY; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84881257599     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-311-4_13     Document Type: Article

References (62)

1. Chua HN, Wong L (2008) Increasing the reliability of protein interactomes. Drug Discov Today 13:652-658
2. Miernyk JA, Thelen JJ (2008) Biochemical approaches for discovering protein-protein interactions. Plant J 53:597-609
3. Smith C (2003) Drug target validation: hitting the target. Nature 422:341
4. Walsh CT, Garneau-Tsodikova S, Gatto GJJ (2001) Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed 44:7342-7372
5. Paweletz CP, Liotta LA, Petricoin EF (2001) New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 57:160-163
6. Mueller C, Liotta LA, Espina V (2010) Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 4:461-481
7. Pierobon M, VanMeter AJ, Moroni N et al (2012) Reverse-phase protein microarrays. Methods Mol Biol 823:215-235
8. Espina V, Wulfkuhle J, Calvert VS et al (2008) Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol Biol 441:113-128
9. Wilson B, Liotta LA, Petricoin E (2010) Monitoring proteins and protein networks using reverse phase protein arrays. Dis Markers 28:225-232
10. Espina V, Wulfkuhle JD, Calvert VS et al (2007) Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol 383:321-336
11. Gallagher RI, Silvestri A, Petricoin EF et al (2011) Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol 723:275-301
12. Brase JC, Mannsperger H, Sultmann H et al (2011) Antibody-mediated signal amplification for reverse phase protein array-based protein quantification. Methods Mol Biol 785:55-64
13. Brase JC, Mannsperger H, Frohlich H et al (2010) Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci 8:36
14. Espina V, Woodhouse EC, Wulfkuhle J et al (2004) Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods 290:121-133
15. VanMeter AJ, Rodriguez AS, Bowman ED et al (2008) Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 7:1902-1924
16. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674
17. Sheehan KM, Calvert VS, Kay EW et al (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346-355
18. Improta G, Zupa A, Fillmore H et al (2001) Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 10:3089-3097
19. Agrawal N, Frederick MJ, Pickering CR et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157
20. Frederick MJ, VanMeter AJ, Gadhikar MA et al (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178(2): 548-571
21. Accordi B, Espina V, Giordan M et al (2010) Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. PLoS One (Electronic Resource) 5:e13552
22. Lu Y, Muller M, Smith D et al (2010) Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30:4567-4577
23. Pierobon M, Calvert V, Belluco C et al (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 8:110-117
24. Espina V, Mariani BD, Gallagher RI et al (2010) Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (Electronic Resource) 5:e10240
25. Lavezzari G, Lackner MR (2012) Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays. Methods Mol Biol 795:203-215
26. Martiny-Baron G, Haasen D, D'Dorazio D et al (2011) Characterization of kinase inhibitors using reverse phase protein arrays. Methods Mol Biol 785:79-107
27. Gopal YN, Deng W, Woodman SE et al (2001) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-8747
28. Miller TW, Hennessy BT, Gonzalez-Angulo AM et al (2001) Hyperactivation of phosphatidylinositol- 3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120:2406-2413
29. Wei X, Guo W, Wu S et al (2009) Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 284:16948-16955
30. Espina V, Liotta LA, Petricoin EF (2009) Reverse-phase protein microarrays for theranostics and patient tailored therapy. Methods Mol Biol 520:89-105
31. Stuart D, Sellers WR (2009) Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol 21:304-310
32. Hamburg MA, Collins FS (1922) The path to personalized medicine (Erratum appears in N Engl J Med. 2010 Sep 9;363(11):1092). N Engl J Med 363:301-304
33. Macconaill LE, Garraway LA (2010) Clinical implications of the cancer genome. J Clin Oncol 28:5219-5228
34. Pierobon M, Belluco C, Liotta LA et al (2011) Reverse phase protein microarrays for clinical applications. Methods Mol Biol 785:3-12
35. Zha H, Raffeld M, Charboneau L et al (2004) Similarities of prosurvival signals in Bcl-2- positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 84:235-244
36. Liotta LA, Kohn EC, Petricoin EF (1914) Clinical proteomics: personalized molecular medicine. JAMA 286:2211-2214
37. Espina V, Dettloff KA, Cowherd S et al (2004) Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 4:83-93 (Review) (95 refs)
38. Petricoin EF, Espina V, Araujo RP et al (2001) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67:3431-3440
39. Berg D, Wolff C, Langer R et al (2011) Discovery of new molecular subtypes in oesophageal adenocarcinoma. PLoS One (Electronic Resource) 6:e23985
40. Von H, Stephenson JJ Jr, Rosen P et al (2010) Pilot study using molecular profiling of patients' tumors tofind potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883
41. Liotta LA, Petricoin EF (2012) Regulatory approval pathways for molecular diagnostic technology. Methods Mol Biol 823:409-420
42. Rapkiewicz A, Espina V, Zujewski JA et al (1925) The needle in the haystack: application of breastfine-needle aspirate samples to quantitative protein microarray technology. Cancer 111:173-184
43. Espina V, Mueller C (2012) Reduction of preanalytical variability in specimen procurement for molecular profiling. Methods Mol Biol 823:49-57
44. Silvestri A, Colombatti A, Calvert VS et al (2010) Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 90:787-796
45. Van L, Nordgard SH, Lingjaerde OC et al (1928) Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 107: 16910-16915
46. Hennessy BT, Lu Y, Gonzalez-Angulo AM et al (2010) A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6:129-151
47. Berg D, Wolff C, Malinowsky K et al (2012) Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. J Cell Physiol 227:204-212
48. Gonzalez-Angulo AM, Hennessy BT, Meric- Bernstam F et al (2011) Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8:11
49. Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16):1981-1989
50. Ornstein DK, Gillespie JW, Paweletz CP et al (2000) Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21:2235-2242
51. Mueller C, Edmiston KH, Carpenter C et al (2011) One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One (Electronic Resource) 6:e23780
52. Espina V, Edmiston KH, Heiby M et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998-2018
53. Espina V, Mueller C, Edmiston K et al (2009) Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl 3:874-882
54. Holzer TR, Fulford AD, Arkins AM et al (2011) Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/ MAPK, and p38 MAPK signaling networks. Anticancer Res 31:2073-2081
55. Wolff C, Schott C, Malinowsky K et al (2011) Producing reverse phase protein microarrays from formalin-fixed tissues. Methods Mol Biol 785:123-140
56. Wolff C, Schott C, Porschewski P et al (2011) Successful protein extraction from over-fixed and long-term stored formalin-fixed tissues (Erratum appears in PLoS One. 2011;6(4). doi:10.1371/annotation/a42e114f-a708- 4423-8a3e-a1d8919b9b60). PLoS One (Electronic Resource) 6:e16353
57. Berg D, Malinowsky K, Reischauer B et al (2011) Use of formalin-fixed and paraffinembedded tissues for diagnosis and therapy in routine clinical settings. Methods Mol Biol 785:109-122
58. Spurrier B, Washburn FL, Asin S et al (2007) Antibody screening database for protein kinetic modeling. Proteomics 7:3259-3263
59. Mannsperger H, Uhlmann S, Korf U et al (2011) Utilization of RNAi to validate antibodies for reverse phase protein arrays. Methods Mol Biol 785:45-54
60. Berg D, Hipp S, Malinowsky K et al (2010) Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur J Cancer 46:47-55
61. Espina V, Mueller C, Liotta LA (2011) Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology. Methods Mol Biol 785: 23-43
62. Malinowsky K, Wolff C, Gundisch S et al (2010) Targeted therapies in cancer-challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. J Cancer 2:26-35